EV Biologics Corp, announced that it has closed a $500,000 interest-free loan from a related party. This funding will provide for further development of exosome - and other nanoparticle-enriched biological products, as well as optimization of their scalable, cGMP-compatible, biomanufacturing process. The funds will be also used for comprehensive product analysis by several leading independent laboratories.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5741 USD | -4.65% | -4.65% | -42.59% |
2023 | EV Biologics, Inc. Closes A $500,000 Interest-Free Loan | CI |
2023 | Ev Biologics Completes Production of Cutting-Edge Msc Exosome-Based Therapeutic | CI |
1st Jan change | Capi. | |
---|---|---|
-42.59% | 6.16M | |
+20.24% | 48.59B | |
+8.09% | 16.48B | |
-3.26% | 15.81B | |
-9.89% | 11.24B | |
+35.06% | 9.26B | |
-4.45% | 7.76B | |
+43.06% | 7.76B | |
-5.09% | 7.58B | |
+105.28% | 7.34B |
- Stock Market
- Equities
- YECO Stock
- News EV Biologics, Inc.
- EV Biologics, Inc. Closes A $500,000 Interest-Free Loan